| 2024-10-30 |
[Corrections] Correction to Lancet Respir Med 2020; 8: 696–708 |
|
|
| 2024-10-30 |
[Correspondence] Spirometry in female individuals – Authors' reply |
Philippe Haouzi, Johnathan McCully |
|
| 2024-10-30 |
[Corrections] Correction to Lancet Respir Med 2024; 12: 888–900 |
|
|
| 2024-10-30 |
[Correspondence] Spirometry in female individuals |
Martin R Miller, Brian L Graham, Sanja Stanojevic |
|
| 2024-10-30 |
[Comment] Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis |
Marjolein Drent, Anne-Marie Russell, Lesley Ann Saketkoo, Paolo Spagnolo, Marcel Veltkamp, Athol U Wells, representatives of the sarcoidosis community |
|
| 2024-10-30 |
[Editorial] Antimicrobial resistance: a global health emergency |
The Lancet Respiratory Medicine |
|
| 2024-10-30 |
[Correspondence] Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutation |
Martina Gentzsch, Charles R Esther, Carla M P Ribeiro |
|
| 2024-10-30 |
[News] Phillip Morris sell Vectura after academic freeze-out |
Talha Burki |
|
| 2024-10-30 |
[News] European Respiratory Society International Congress 2024 |
Priya Venkatesan |
|
| 2024-10-30 |
[Comment] Strengthening intensive care: addressing challenges and embracing opportunities |
Elie Azoulay, Maurizio Cecconi, Jan J De Waele |
|
| 2024-10-30 |
[Comment] Serotonin pathway blockade in pulmonary arterial hypertension |
Marcin Kurzyna |
|
| 2024-10-30 |
[Articles] Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial |
Olivier Sitbon, Andris Skride, Jeremy Feldman, Sandeep Sahay, Oksana A Shlobin, Vallerie McLaughlin, Hossein-Ardeschir Ghofrani, David Langleben, Ed Parsley, Gwyn D'Souza, Tonya Marmon, Watiri Kamau-Kelley, Renee Jones, Ravi Grewal, Steve Wring, Michelle |
|
| 2024-10-30 |
[Correspondence] Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership |
Joanne McPeake, Mark Oakes, Colin Graham, Nahid Ahmad, Nazir Lone, Bronwen Connolly, James Lind Alliance Sepsis PSP Steering Group |
|
| 2024-10-30 |
[Articles] Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial |
Surinder S Birring, Linda Cardozo, Roger Dmochowski, Peter Dicpinigaitis, Amna Afzal, Carmen La Rosa, Susan Lu, Allison Martin Nguyen, Ruji Yao, Paul A Reyfman |
|
| 2024-10-30 |
[Comment] Easing the stress of chronic cough |
Marta Dąbrowska, Lorcan McGarvey |
|
| 2024-10-30 |
[Comment] New thinking and a new direction in bronchiectasis |
Ian D Pavord |
|
| 2024-10-30 |
[Articles] Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, rando |
Yoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, Hidehito Horinouchi, Yasuto Yoneshima, Hidetoshi Hayashi, Koichi Azuma, Satoshi Hara, Seiji Niho, Ryo Morita, Masafumi Yamaguchi, Toshihide Yokoyama, Kiyotaka Yoh, Takayasu Kurata, Hiroaki Okamoto, Mas |
|
| 2024-10-30 |
[Spotlight] Fatal dyspnoea at the Palace of Versailles |
Emmanuel Drouin, Serge Wasersztrum, Arnaud Chambellan |
|
| 2024-10-30 |
[Comment] Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study |
Molly S C Li, Stephanie P L Saw, Alfredo Addeo |
|
| 2024-10-30 |
[Comment] Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis |
Katherine Odem-Davis, Jennifer L Taylor-Cousar |
|
| 2024-10-30 |
[Articles] The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study |
Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, Isabelle Durieu, Véronique Houdouin, Camille Audousset, Julie Macey, Dominique Grenet, Michele Porzio, Marlène Murris-Espin, Philippe Reix, Mélisande Baravalle, Chantal Belleguic, Laurent |
|
| 2024-10-30 |
[Health-care Development] Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review |
Sjanna B Besteman, Debby Bogaert, Louis Bont, Asuncion Mejias, Octavio Ramilo, Daniel M Weinberger, Ron Dagan |
|
| 2024-10-30 |
[Review] Rethinking bronchiectasis as an inflammatory disease |
Merete B Long, Sanjay H Chotirmall, Michal Shteinberg, James D Chalmers |
|
| 2024-10-02 |
[Correspondence] Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts |
James Greenan-Barrett, Yohhei Hamada, Katherine L Fielding, Mahdad Noursadeghi, Rishi K Gupta |
|
| 2024-10-02 |
[Correspondence] Anti-interleukin-4 receptor therapy for COPD with dupilumab? |
J Christian Virchow |
|
| 2024-10-02 |
[Comment] Reflections 5 years on from the approval of ETI therapy |
Peter G Middleton, Jennifer L Taylor-Cousar |
|
| 2024-10-02 |
[Editorial] Extreme heat: holistic thinking in respiratory medicine |
The Lancet Respiratory Medicine |
|
| 2024-10-02 |
[Articles] Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months |
Charles S Haworth, Michal Shteinberg, Kevin Winthrop, Alan Barker, Francesco Blasi, Katerina Dimakou, Lucy C Morgan, Anne E O'Donnell, Felix C Ringshausen, Oriol Sibila, Rachel M Thomson, Kevin J Carroll, Federica Pontenani, Paola Castellani, James D Chal |
|
| 2024-10-02 |
[Comment] PROMISing results for inhaled antibiotics in bronchiectasis |
Marta María García Clemente, Guillermo Suárez Cuartín |
|
| 2024-10-02 |
[Articles] Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled tr |
Baohui Han, Trevor Feinstein, Yuankai Shi, Gongyan Chen, Yu Yao, Chunhong Hu, Jianhua Shi, Jifeng Feng, Huijuan Wu, Ying Cheng, Qi-sen Guo, Zhijun Jie, Feng Ye, Yiping Zhang, Zhihua Liu, Weidong Mao, Liangming Zhang, Junguo Lu, Jun Zhao, Lyudmila Bazhenov |
|
| 2024-10-02 |
[Comment] Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial |
Rafael Rosell, María González-Cao, Miguel Angel Molina-Vila |
|
| 2024-10-02 |
[Articles] Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial |
Irene J Higginson, Sarah T Brown, Adejoke O Oluyase, Peter May, Matthew Maddocks, Massimo Costantini, Sabrina Bajwah, Charles Normand, Claudia Bausewein, Steffen T Simon, Karen Ryan, David C Currow, Miriam J Johnson, Simon P Hart, Hannah Mather, Malgorzat |
|
| 2024-10-02 |
[Comment] The ongoing battle against breathlessness |
Kris Mooren, Huib A M Kerstjens |
|
| 2024-10-02 |
[Comment] Choice overload for RSV prevention—how to form your opinion |
Natasha Halasa, Louis Bont |
|
| 2024-10-02 |
[Spotlight] Louis Bont – leading efforts to find an RSV vaccine |
Tony Kirby |
|
| 2024-10-02 |
[Series] Early-life respiratory syncytial virus disease and long-term respiratory health |
Heather J Zar, Ferdinand Cacho, Tahira Kootbodien, Asuncion Mejias, Justin R Ortiz, Renato T Stein, Tina V Hartert |
|
| 2024-10-02 |
[Series] Respiratory syncytial virus infections in adults: a narrative review |
Joanne G Wildenbeest, David M Lowe, Joseph F Standing, Christopher C Butler |
|
| 2024-10-02 |
[Comment] ECMO: more than just a bridge over troubled waters? |
Ryan Ruiyang Ling, Kollengode Ramanathan, Kiran Shekar |
|
| 2024-10-02 |
[Comment] Continuing ECMO with no possible transition to recovery or transplant |
Alexander Supady, William L Allen, Thaddeus M Pope |
|
| 2024-10-02 |
[News] The UK COVID-19 Inquiry and critical care |
Priya Venkatesan |
|
| 2024-10-02 |
[Spotlight] One lung but many laughs at the Edinburgh Festival Fringe |
Peter Ranscombe |
|
| 2024-10-02 |
[Spotlight] Saving lives with oxygen and monocytes at Edinburgh Fringe |
Peter Ranscombe |
|
| 2024-10-02 |
[Articles] High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial |
Jiayi Yu, Leilei Jiang, Lina Zhao, Xue Yang, Xiaomin Wang, Dan Yang, Minglei Zhuo, Hanxiao Chen, Wei Huang, Zhengfei Zhu, Min Zhang, Yipeng Song, Quanfu Li, Zhanshu Ma, Qifeng Wang, Yanli Qu, Rong Yu, Huiming Yu, Jun Zhao, Anhui Shi, Trial Management Grou |
|
| 2024-10-02 |
[Comment] New strategies for patients with limited-stage small-cell lung cancer |
Famke L Schneiders, Suresh Senan |
|
| 2024-10-02 |
[Correspondence] Sedation targets in the ICU: thinking beyond protocols |
Bruna Brandao Barreto, Mariana Luz, Dimitri Gusmao-Flores |
|
| 2024-10-02 |
[Spotlight] James Chalmers: A maverick making an impact in bronchiectasis |
Peter Ranscombe |
|
| 2024-08-29 |
[Correspondence] Further insights into MARS 2 |
Yumna Ahmed, Agha Muhammad Hammad Khan, Calogero Casa, Ahmed Nadeem Abbasi |
|
| 2024-08-29 |
[Correspondence] Further insights into MARS 2 |
Peter Zhan, Daniel J Boffa, Gavitt A Woodard |
|
| 2024-08-29 |
[Correspondence] Further insights into MARS 2 |
Marcello Migliore |
|
| 2024-08-29 |
[Correspondence] Further insights into MARS 2 – Authors' reply |
Eric Lim, Chris Rogers, MARS 2 trialists |
|
| 2024-08-29 |
[Editorial] FLiRTing with danger as SARS-CoV-2 variants evolve |
The Lancet Respiratory Medicine |
|
| 2024-08-29 |
[Comment] Patient-reported outcomes: missing in asthma remission |
Amy Hai Yan Chan, Paul Leong, John Politis, Vanessa M McDonald, Philip Bardin |
|
| 2024-08-29 |
[Articles] Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study |
Margaux M I Meslé, Jeremy Brown, Piers Mook, Mark A Katz, José Hagan, Roberta Pastore, Bernhard Benka, Monika Redlberger-Fritz, Nathalie Bossuyt, Veerle Stouten, Catharina Vernemmen, Elisabet Constantinou, Marek Maly, Jan Kynčl, Ondrej Sanca, Tyra Grove K |
|
| 2024-08-29 |
[Comment] Impact of COVID-19 vaccination programmes in Europe: lives saved and lessons learned |
Oliver J Watson, Alexandra B Hogan |
|
| 2024-08-29 |
[News] US FDA approves menthol e-cigarette products |
Bryant Furlow |
|
| 2024-08-29 |
[Comment] Foritinib, a type II ROS1 inhibitor for NSCLC |
Jii Bum Lee, Sai-Hong Ignatius Ou |
|
| 2024-08-29 |
[Articles] Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study |
Jin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, Mingjun Li, Zhiye Zhang, Ying Cheng, Yun Fan, Hongming Pan, Baoqing Wang, Gongyan Chen, Ke Wang, Liyan Jiang, Yanping Hu, Jianhua Shi, Xiaorong Dong, Cuimin Ding, Yunpeng Liu, Zhe Liu, Wangjun Liao, Wei Li, |
|
| 2024-08-29 |
[News] US Supreme Court overturns Chevron doctrine |
Bryant Furlow |
|
| 2024-08-29 |
[Articles] Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation |
Hernan P Fainberg, Yuben Moodley, Isaac Triguero, Tamera J Corte, Jannie M B Sand, Diana J Leeming, Morten A Karsdal, Athol U Wells, Elisabetta Renzoni, John Mackintosh, Dino B A Tan, Roger Li, Joanne Porte, Rebecca Braybrooke, Gauri Saini, Simon R Johnso |
|
| 2024-08-29 |
[Review] Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients |
Simon Feys, Agostinho Carvalho, Cornelius J Clancy, Jean-Pierre Gangneux, Martin Hoenigl, Katrien Lagrou, Bart J A Rijnders, Laura Seldeslachts, Lore Vanderbeke, Frank L van de Veerdonk, Paul E Verweij, Joost Wauters |
|
| 2024-08-29 |
[Comment] Biomarker-defined endotypes of pulmonary fibrosis |
A Scott McCall, Jonathan A Kropski |
|
| 2024-08-29 |
[Spotlight] Alin Gragossian: from emergency medicine resident to heart transplant recipient |
Tony Kirby |
|
| 2024-08-29 |
[Spotlight] Fasting in Ramadan and respiratory diseases |
Talha Burki |
|
| 2024-08-29 |
[Articles] Hypothermia for expanded criteria organ donors in kidney transplantation in France (HYPOREME): a multicentre, randomised controlled trial |
The HYPOREME Trial Group |
|
| 2024-08-29 |
[Comment] Mild hypothermia for expanded criteria kidney donors: balancing evidence and uncertainty |
Riccardo Campi, Vincenzo Li Marzi, Sergio Serni |
|
| 2024-08-29 |
[Articles] Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial |
Claire Elizabeth Wainwright, Suzanna Vidmar, Vicki Anderson, Pierrick Bourgeat, Catherine Byrnes, John Brooke Carlin, Joyce Cheney, Peter Cooper, Andrew Davidson, Nicholas Gailer, Jasmin Grayson-Collins, Alexandra Quittner, Colin Robertson, Olivier Salvad |
|
| 2024-08-29 |
[Comment] Early exposure to general anaesthesia: considerations for age-related vulnerability and behavioural outcomes |
Daniil P Aksenov |
|
| 2024-07-31 |
[Correspondence] The recent explosion in snortable energy powder consumption |
Jérémie Pourchez, Clément Mercier, Lara Leclerc, Valérie Forest |
|
| 2024-07-31 |
[Editorial] Household air pollution: a neglected threat |
The Lancet Respiratory Medicine |
|
| 2024-07-31 |
[Correspondence] Concerning the use of aminoglycosides in ventilator-associated pneumonia |
Simone Y M de Jong, G Jan Zijlstra |
|
| 2024-07-31 |
[Correspondence] Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply |
Srishti Chhabra, Yin Mo |
|
| 2024-07-31 |
[Corrections] Correction to Lancet Respir Med 2024; 12: 642–54 |
|
|
| 2024-07-31 |
[Articles] Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial |
Paul Little, Jane Vennik, Kate Rumsby, Beth Stuart, Taeko Becque, Michael Moore, Nick Francis, Alastair D Hay, Theo Verheij, Katherine Bradbury, Kate Greenwell, Laura Dennison, Sian Holt, James Denison-Day, Ben Ainsworth, James Raftery, Tammy Thomas, Chri |
|
| 2024-07-31 |
[Comment] Treating acute respiratory illness: the need to be proactive |
Evangelos J Giamarellos-Bourboulis |
|
| 2024-07-31 |
[News] Whooping cough cases rising |
Priya Venkatesan |
|
| 2024-07-31 |
[Correspondence] Potential for personalised and biomarker-guided COPD self-treatment approaches |
Anke Lenferink, Emanuel Citgez, Paul D L P M van der Valk, Job van der Palen, Tanja W Effing, Marjolein G J Brusse-Keizer |
|
| 2024-07-31 |
[Comment] Moving forward in IPF: lessons learned from clinical trials |
Ganesh Raghu, Thomas R Fleming |
|
| 2024-07-31 |
[Correspondence] Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials |
Brady Thomas, Patrick McNamara, Jennifer Bermick |
|
| 2024-07-31 |
[Correspondence] Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials – Authors' reply |
John Lowe, Janet Berrington, David Gillespie, Mark Turner, Sailesh Kotecha |
|
| 2024-07-31 |
[News] 2024 American Thoracic Society International Conference |
Priya Venkatesan |
|
| 2024-07-31 |
[Articles] Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial |
Ziming Li, Xiaomin Dang, Dingzhi Huang, Shi Jin, Weiwei Li, Jianhua Shi, Xicheng Wang, Yiping Zhang, Zhengbo Song, Junping Zhang, Wu Zhuang, Xuewen Liu, Liyan Jiang, Xiangjiao Meng, Mingfang Zhao, Jianying Zhou, Liangming Zhang, Pingli Wang, Hui Luo, Junq |
|
| 2024-07-31 |
[Comment] Tackling KRASG12C-mutated non-small-cell lung cancer: iteration and exploration |
Jia Luo, Liza C Villaruz |
|
| 2024-07-31 |
[Personal View] When to intubate in acute hypoxaemic respiratory failure? Options and opportunities for evidence-informed decision making in the intensive care unit |
Kevin G Lee, Oriol Roca, Jonathan D Casey, Matthew W Semler, Georgiana Roman-Sarita, Christopher J Yarnell, Ewan C Goligher |
|
| 2024-07-31 |
[Comment] Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts |
Gavin Churchyard, Nicole Salazar-Austin |
|
| 2024-07-31 |
[Articles] Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing studies |
Leonardo Martinez, James A Seddon, C Robert Horsburgh, Christoph Lange, Anna M Mandalakas, TB Contact Studies Consortium |
|
| 2024-07-31 |
[Comment] Treatment effects on functional outcomes in trials with severely ill patients |
Edmond S W Ng |
|
| 2024-07-31 |
[Articles] Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial |
Matthew F Mart, Leanne M Boehm, Amy L Kiehl, Michelle N Gong, Atul Malhotra, Robert L Owens, Babar A Khan, Margaret A Pisani, Gregory A Schmidt, R Duncan Hite, Matthew C Exline, Shannon S Carson, Catherine L Hough, Peter Rock, Ivor S Douglas, Daniel J Fei |
|
| 2024-07-31 |
[Articles] Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial |
John Lowe, David Gillespie, Ali Aboklaish, Tin Man Mandy Lau, Claudia Consoli, Malavika Babu, Mark Goddard, Kerenza Hood, Nigel Klein, Emma Thomas-Jones, Mark Turner, Marie Hubbard, Julian Marchesi, Janet Berrington, Sailesh Kotecha |
|
| 2024-07-31 |
[Comment] Azithromycin for the prevention of chronic lung disease of prematurity: not a silver bullet |
Abdul Razak |
|
| 2024-06-26 |
[Corrections] Correction to Lancet Respir Med 2024; 12: 544–55 |
|
|
| 2024-06-26 |
[Spotlight] Protecting respiratory health of athletes: an Olympic challenge |
James H Hull, Hege Clemm, Vibeke Backer, Michael Koehle, Margo Mountjoy, Martin Schwellnus, J Tod Olin |
|
| 2024-06-26 |
[Spotlight] Living with spinal muscular atrophy while working in critical care |
Linsey Wehner, Atul Malhotra, Jeremy Orr |
|
| 2024-06-26 |
[Editorial] Respiratory syncytial virus vaccines: the future is bright |
The Lancet Respiratory Medicine |
|
| 2024-06-26 |
[Articles] High-flow nasal oxygen for children's airway surgery to reduce hypoxaemic events: a randomised controlled trial |
Susan Humphreys, Britta S von Ungern-Sternberg, Fiona Taverner, Andrew Davidson, Justin Skowno, Ben Hallett, David Sommerfield, Neil Hauser, Tara Williams, Susan Spall, Trang Pham, Tiffany Atkins, Mark Jones, Emma King, Laura Burgoyne, Philip Stephens, Sh |
|
| 2024-06-26 |
[Corrections] Correction to Lancet Respir Med 2024; 12: 207–16 |
|
|
| 2024-06-26 |
[Corrections] Correction to Lancet Respir Med 2024; 12: 183–85 |
|
|
| 2024-06-26 |
[Comment] Paediatric anaesthesia: it is not only what you do, but how you do it |
Thomas Engelhardt, Nicola Disma |
|
| 2024-06-26 |
[Comment] Continuous positive airway pressure is here to stay |
Atul Malhotra, Jeremy H Pettus |
|
| 2024-06-26 |
[Comment] Re-evaluating the role of CPAP in OSA management amid obesity pharmacology advancements |
Neomi Shah |
|
| 2024-06-26 |
[Articles] Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial |
Robert P Frantz, Vallerie V McLaughlin, Sandeep Sahay, Pilar Escribano Subías, Ronald L Zolty, Raymond L Benza, Richard N Channick, Kelly M Chin, Anna R Hemnes, Luke S Howard, Olivier Sitbon, Jean-Luc Vachiéry, Roham T Zamanian, Matt Cravets, Robert F Ros |
|
